Melatonin (Slenyto®) is recommended as an option for use within NHS Wales for the treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and/or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.